At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
ZD1839 (Iressa) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy With Stereotactic Body Frame Immobilization for Patients With Advanced Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted May 22, 2006·Updated May 4, 2025
In Brief
A Phase 1 clinical trial evaluating ZD1839 (Iressa) and Thoracic Radiotherapy for Non-Small Cell Lung Carcinoma (NSCLC). Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Carcinoma (NSCLC)
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2003
First PostedMay 2006
Primary CompletionApr 2008
Study CompletionSep 2010
TodayJul 2026
First PostedMay 22, 2006
Enrollment StartDec 1, 2003
Primary CompletionApr 1, 2008
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.1 years ago
Interventions
ZD1839 (Iressa)drug
Thoracic Radiotherapyradiation